# BeBetter Med

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bebetter-med

- Industry: Pharmaceuticals
- Headquarters: Guangzhou, China
- Website: www.bebettermed.cn
- Latest round: Series A (May 18, 2020)
- Investors on record: 3

## About

Founded in 2012 and based in Guangzhou, China, BeBetter Med Inc.  operates as a pharmaceutical company which focuses on molecular science and cancer treatment. The chairman and general manager Dr. Changge Qian is the postdoctoral fellow at the National Academy of Sciences, he served as the vice president of Curis, Inc. and obtained more than 40 authorized patents in the United States and more than 20 authorized patents in China, published 37 international invention patents and more than 30 academic papers. In October 2025, Guangzhou BeBetter Medicine Technology Co., Ltd. ?raised CNY 1.6 billion?in an IPO, selling?90 million shares?at?CNY 17.78 per share at Shanghai Stock Exchange, under the ticker "688759".

The company self-developed products include breast cancer, lung cancer, colon cancer inhibitor BEBT-908, breast cancer inhibitor BEBT-209, mutant lung cancer inhibitor BEBT-109, autoimmune disease inhibitor ZXBT-1158, psoriasis inhibitor BEBT-305, mutant non Small cell lung cancer, colorectal cancer inhibitor BEBT-607, non-alcoholic steatohepatitis inhibitor BEBT-503 and diabetes and obesity inhibitor BEBT-808.

The company generates revenue by doing research, development and providing innovative small-molecule drugs for tumors, cancer and other related products.

## Funding rounds

- Series A, May 18, 2020 — Yuexiu Industrial Investment Funds Management, Sanmei Capital, Shenzhen Lucky Source Investment Management

## Investors

- Yuexiu Industrial Investment Funds Management (https://capitalatlas.ai/funds/yuexiu-industrial-investment-funds-management) — Series A
- Sanmei Capital (https://capitalatlas.ai/funds/sanmei-capital) — Series A
- Shenzhen Lucky Source Investment Management (https://capitalatlas.ai/funds/shenzhen-lucky-source-investment-management) — Series A